Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis

Hernández-Cruz, Blanca; Kiltz, Uta; Avouac, Jérôme; Treuer, Tamas; Haladyj, Ewa; Gerwien, Jens; Gupta, Chandreyee Dutta; Conti, Fabrizio

doi:10.1007/s40744-023-00591-9

Cited by 6 publications

(1 citation statement)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 – 8 Tofacitinib was the first JAK1, JAK2, and JAK3 inhibitor discovered, and is currently approved for treatment of inflammatory arthritides [RA, ankylosing spondylitis (AS), psoriatic arthritis (PsA), juvenile idiopathic arthritis] and ulcerative colitis (UC). 7 , 9 Baricitinib mitigates arthritic symptomatology for patients with rheumatoid arthritis by inhibiting JAK1 and JAK2, 10 and is also licensed for atopic dermatitis and alopecia areata. 6 The third JAK inhibitor developed was upadacitinib, which selectively inhibits JAK1 isoform contrary to tofacitinib and baricitinib.…”

Section: Introductionmentioning

confidence: 99%

Focus on Filgotinib in Rheumatoid Arthritis: A Trial-Based Review

Skouvaklidou,

Deligeorgakis,

Skalkou

et al. 2024

MJR

View full text Add to dashboard Cite

Janus kinases (JAK)/Signal Transducer and Activator of Transcription (STAT) pathway is involved in pathophysiologic cascade of a notable number of rheumatic diseases. The development of JAK inhibitors has expanded treatment choices in rheumatoid arthritis (RA) with a sustained class-effect efficacy. Filgotinib is a novel selective inhibitor of JAK1 isoform licensed for use in RA and ulcerative colitis. In this review we aim to present an analysis of filgotinib’s efficacy and drug-specific safety warnings. Patients with RA with or without concomitant conventional synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) (naïve or experienced) and those who have failed biologic Disease-Modifying Antirheumatic Drugs (bDMARDs) were examined in randomised clinical trials. Filgotinib was also tested against placebo, methotrexate, or adalimumab. Long-term extension trials provide insights for up to four years of continuous filgotinib administration. Beneficial effects are depicted in both disease activity parameters and quality of life indexes in moderate or severe RA with a longitudinal efficacy. In head-to-head comparison with adalimumab, filgotinib 200 mg was non-inferior. Adverse effects alerts are marked by the elevated risk of infectious adverse effects with the exception of herpes zoster infection, which has a low incidence.

show abstract

Section: Introductionmentioning

confidence: 99%

Focus on Filgotinib in Rheumatoid Arthritis: A Trial-Based Review

Skouvaklidou,

Deligeorgakis,

Skalkou

et al. 2024

MJR

View full text Add to dashboard Cite

show abstract

Clinical effectiveness of baricitinib and abatacept in patients with rheumatoid arthritis

Asai,

Takahashi,

Terabe

et al. 2024

Int J of Rheum Dis

View full text Add to dashboard Cite

AimThe objective of this study was to compare the clinical effectiveness of baricitinib and abatacept in patients with rheumatoid arthritis (RA).MethodsThis study included 274 patients treated with abatacept and 241 treated with baricitinib who were followed for >52 weeks. Potential treatment selection bias was addressed by using inverse probability of treatment weighting. The paired t‐test was used to assess differences in Clinical Disease Activity Index (CDAI) score relative to baseline. A generalized estimating equation was used to compare the two treatment groups.ResultsThe estimated mean CDAI score was 18.2 at baseline and significantly decreased to 12.6 at 4 weeks, 8.9 at 12 weeks, 7.4 at 24 weeks, and 6.1 at 52 weeks in the abatacept group. The estimated mean CDAI score was 18.6 at baseline and significantly decreased to 9.5 at 4 weeks, 6.5 at 12 weeks, 5.7 at 24 weeks, and 5.5 at 52 weeks in the baricitinib group. The baricitinib group had significantly lower CDAI scores at 4, 12, and 24 weeks compared to the abatacept group. Subgroup analyses revealed that this difference was evident among patients with high disease activity and without concomitant use of methotrexate but was less pronounced among those with remission to moderate disease activity status with methotrexate use.ConclusionBoth baricitinib and abatacept were effective in reducing disease activity in patients with RA. Baricitinib demonstrated potential advantages over abatacept in terms of early disease control, particularly in patients with high disease activity and without methotrexate use.

show abstract

Is Baricitinib Effective and Safe for Patients with Difficult-to-Treat Rheumatoid Arthritis? Comparative Data with the Rheumatoid Arthritis Group of Rheumatoid Arthritis Not Difficult to Treat

Ekin,

Misirci,

Görünen

et al. 2024

Med Princ Pract

View full text Add to dashboard Cite

Objective: This study investigates the efficacy and safety of baricitinib, an oral targeted synthetic Disease Modifying Anti-Rheumatic Drugs (DMARD), in patients with difficult-to-treat rheumatoid arthritis (D2T RA) compared to those without, aiming to determine its potential as an alternative treatment for D2T RA. Subject and Methods: A total of 78 patients participated in this retrospective cohort study, with 33 meeting the D2T RA criteria and 45 were in the non-D2T RA group. Various clinical and laboratory parameters, adverse events, and disease activity indices were assessed, alongside drug efficacy and survival rates. Results: Patients with D2T RA exhibited higher seronegativity, prior use of bDMARDs and cDMARDs, and longer disease duration. Both groups experienced reductions in VAS and DAS28 scores, as well as SDAI, CDAI, HAQ, CRP, and ESR levels at baseline and 3, 6, and 12 months post-baricitinib initiation, with sustained efficacy observed over 12 months. The most prevalent adverse event was infection (28.21%). Although initial drug survival rates were similar between groups, the non-D2T RA group demonstrated higher rates at 24 months (46.70% vs. 59.40%). Subgroup analyses showed comparable survival rates between D2T RA and non-D2T RA groups, whether treated with baricitinib alone or in combination with methotrexate or leflunomide. Conclusion: Despite potential treatment resistance, patients meeting the D2T RA criteria shared similar safety and efficacy profiles with those non-D2T RA. Baricitinib emerges as a promising treatment option for D2T RA patients, offering effectiveness and safety comparable to the non-D2T RA group.

show abstract

Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis

Cited by 6 publications

References 101 publications

Focus on Filgotinib in Rheumatoid Arthritis: A Trial-Based Review

Focus on Filgotinib in Rheumatoid Arthritis: A Trial-Based Review

Clinical effectiveness of baricitinib and abatacept in patients with rheumatoid arthritis

Is Baricitinib Effective and Safe for Patients with Difficult-to-Treat Rheumatoid Arthritis? Comparative Data with the Rheumatoid Arthritis Group of Rheumatoid Arthritis Not Difficult to Treat

Contact Info

Product

Resources

About